GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors

Autor: Vincent Delwail, Jean-Ehrland Ricci, Isabelle Peyrottes, Celine Delpech-Debiais, Sandrine Marchetti, Julie Reverso-Meinietti, Jacqueline Lehmann-Che, Gabriel Brisou, Jozef P. Bossowski, Manuel Grima-Reyes, Christiane Copie-Bergman, Camila Rubio-Patiño, Konstantina Fragaki, Eric de Kerviler, Véronique Paquis-Flucklinger, Thierry Jo Molina, Frederic Peyrade, Annabelle Mouchotte, Tony Petrella, Emma Proïcs, Bertrand Nadel, Els Verhoeyen, Bruno Taillan, Richard Delarue, Catherine Thieblemont, Laetitia Shintu, Agnès Paquet, Rana Mhaidly, Johanna Chiche, Elodie Villa, Georges Garnier, Pascal Barbry, Josette Brière, Damien Ambrosetti, Nicolas Mounier, André Bosly, Jean-François Michiels

Publikováno v: CELL METABOLISM
CELL METABOLISM, 2019, 29 (6), pp.1243+. ⟨10.1016/j.cmet.2019.02.002⟩
Cell metabolism, Vol. 29, no.6, p. 1243-1257.e10 (2019)
Cell Metabolism
Cell metabolism, Vol. 29, no. 6, p. 1243-1257 (2019)

International audience; Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease treated with anti-CD20-based immuno-chemotherapy (R-CHOP). We identified that low levels of GAPDH predict a poor response to R-CHOP treatment. Importantly, we de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8410b43c6f44f491c893803752071a6e
https://hal.archives-ouvertes.fr/hal-02359440/file/S155041311930066X.pdf